JO
IBRX icon

John Overdeck’s ImmunityBio IBRX Stock Holding History

John Overdeck’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.2M Buy
11,097,106
+6,711,606
+153% +$50.8M 0.07% 317
2026
Q1 		$33.6M Sell
4,385,500
-332,343
-7% -$2.28M 0.03% 674
2025
Q4 		$9.34M Buy
4,717,843
+2,109,983
+81% +$4.78M 0.01% 1173
2025
Q3 		$6.42M Buy
2,607,860
+1,805,297
+225% +$4.65M 0.01% 1266
2025
Q2 		$2.12M Buy
802,563
+778,763
+3,272% +$2.09M ﹤0.01% 1801
2025
Q1 		$71.6K Sell
23,800
-4,517
-16% -$13.7K ﹤0.01% 3002
2024
Q4 		$72.5K Buy
+28,317
New +$118K ﹤0.01% 3006
2021
Q3 		– Sell
-85,579
Closed -$1.22M – 4451
2021
Q2 		$1.22M Buy
+85,579
New +$1.41M ﹤0.01% 2306
2020
Q4 		– Sell
-617,599
Closed -$4.28M – 3518
2020
Q3 		$4.28M Buy
+617,599
New +$6.16M 0.02% 871
2020
Q2 		– Sell
-36,398
Closed -$105K – 3198
2020
Q1 		$105K Buy
+36,398
New +$182K ﹤0.01% 2835
2019
Q1 		– Sell
-72,704
Closed -$84K – 3230
2018
Q4 		$84K Buy
+72,704
New +$166K ﹤0.01% 2829

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

John Overdeck's IBRX Position: Q2 2026 in Review

John Overdeck increased its ImmunityBio (IBRX) stake by 153% in Q2 2026, buying an estimated $50.8M and bringing the position to 11,097,106 shares worth $97.2M. The position accounts for 0.07% of the portfolio, ranked #317.

John Overdeck first reported a position in IBRX in Q4 2018 and has held it in 11 quarters since. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • John Overdeck held 11,097,106 shares of ImmunityBio worth $97.2M as of Q2 2026.
  • John Overdeck bought 6,711,606 ImmunityBio shares in Q2 2026, an estimated $50.8M.
  • ImmunityBio made up 0.07% of John Overdeck's portfolio in Q2 2026, its #317 holding.
  • John Overdeck first reported a position in ImmunityBio in Q4 2018 and has held it in 11 quarters since.
  • 402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.